Head to head
Cytek Biosciences vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: CTKB · ABT
CTKB
Cytek Biosciences
5.43+1.31%
1-year price shape — +38% over the period
Quant Rating B · 77/100
vs
ABT
Abbott Laboratories
99.60+1.13%
1-year price shape — -24% over the period
Quant Rating D · 16/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| CTKB | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Medical Devices |
| Last price | 5.43 | 99.60 |
| Change today | +1.31% | +1.13% |
| 1-year return | +37.8% | -23.6% |
| Market cap | $705.81M | $172.35B |
| 52-week range | 3.31 – 6.21 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -8.62 | 32.23 |
| P/E percentile, own 5-yr range | 73rd | 62nd |
| P/B | 2.19 | 3.37 |
| Dividend yield | 0.00% | 2.45% |
| Profitability & growth | ||
| EPS (TTM) | -0.52 | 3.72 |
| Net profit (TTM) | $-67.59M | $6.44B |
| Revenue (TTM) | $206.71M | $46.59B |
| Revenue growth (YoY) | +5.6% | +13.0% |
| Gross margin | 53.2% | 56.6% |
| Operating margin | -21.6% | 15.8% |
| Net margin | -39.0% | 11.6% |
| Free cash flow (TTM) | $-12.17M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 63.4% | 81.1% |
| Insider activity (12mo) | 37 buy / 13 sell | 36 buy / 12 sell |
| Short interest (% of float) | 4.0% | 0.8% |
| Analyst consensus | 33% buy / 67% hold (3) | 100% buy (14) |
| Analyst price target | $6 (+10%) | $126 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | B (77) | D (16) |
| Company | ||
| Employees | 702 | 115,000 |
| Founded | 1992 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.